drugset / Trial / NCT01910441

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

NCT01910441

Phase 4 Terminated 95 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients.

Timeline

Start
2013-07
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule 1 mg
Comparator Glimepiride Small molecule 6 mg
Subject Vildagliptin Other / unclassified 50 mg
Background Metformin Small molecule 1000 mg
Background Metformin Small molecule 1500 mg